©2022 Stanford Medicine
Brief Telehealth CBT-I Intervention in the Context of the COVID-19 Pandemic
Not Recruiting
Trial ID: NCT04409743
Purpose
The purpose of this study is to investigate whether an empirically validated treatment for
insomnia (CBT-I) administered early in the course of sleep disturbance can prevent insomnia
disorder or lessen negative mental health outcomes in the wake of the COVID-19 crisis in
adults.
Official Title
Harnessing Telehealth to Mitigate the Impact of the COVID-19 Pandemic on Sleep, Suicidality, and Neuropsychiatric Symptoms
Stanford Investigator(s)
Eligibility
Inclusion Criteria:
- Age 18 years or older
- Access to the internet
- Subjective complaint of sleep disturbance (ISI ≥10) that began after March 1, 2020 or
the COVID-19 Pandemic (self-reported during DUKE Interview)
- Lives in the United States
Exclusion Criteria:
- Presence of suicidal ideation representing high risk as measured by the
Sheehan-Suicide Tracking Scale (S-STS).
- Use of medication specifically prescribed for sleep disturbance and unwilling or
unable to discontinue more than one week prior to baseline data collection.
- Current or lifetime history of bipolar disorder or psychosis
- Current substance abuse or dependence
- Not able to verbalize understanding of involvement in research and provide written,
informed consent
- Not fluent or literate in English
- Unstable pharmacotherapy for other mental health disorders
- Severe impediment to vision, hearing, and/or hand movement, likely to interfere with
the ability to complete assessments, or are unable and/or unlikely to follow study
protocols
- Working rotating shift that overlaps with 2400h
Intervention(s):
behavioral: Remote Cognitive Behavioral Therapy for Insomnia
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Andrea Goldstein-Piekarski, PhD
650-497-9414